<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182232</url>
  </required_header>
  <id_info>
    <org_study_id>1199.5</org_study_id>
    <nct_id>NCT02182232</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination
      with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events according to Common Terminology Criteria for Adverse Events (version 3.0) associated with increasing doses of BIBF 1120</measure>
    <time_frame>up to day 126</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BIBF 1120 in combination with carboplatin and paclitaxel</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose plasma concentration (Cpre)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response according to response evaluation criteria in solid tumors (RECIST)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from best response to onset of tumor progression</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start of treatment to time of documented tumor progression</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve (AUC) from 0 to 12 hours (AUC0-12)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to the last quantifiable drug concentration (AUC0-tz)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate constant (λz) for BIBF 1120</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to 24 hours (AUC0-24) for paclitaxel</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 extrapolated to 48 hours (AUC0-48) for paclitaxel</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC0-∞ that is obtained by extrapolation (% AUCtz-∞)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after intravenous administration (MRTiv) for paclitaxel and carboplatin</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clearance (CL/F)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during the terminal phase (Vz)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to 24 hours (AUC0-24) for carboplatin</measure>
    <time_frame>Day 1 and 22 in the treatment time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration 21 hours after start of infusion (C21) for carboplatin</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration 24 hours after start of infusion (C24) for paclitaxel</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBF 1120 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
    <arm_group_label>BIBF 1120 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients with histologically or cytologically confirmed Stage IIIB
             (including pleural effusion), IV or recurrent NSCLC

          2. Bi-dimensionally measurable disease by one or more techniques (CT, MRI, X-ray)

          3. Age 18 years or older

          4. Life expectancy of at least three (3) months

          5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1

          6. Written informed consent that is consistent with ICH-GCP guidelines

        Exclusion Criteria:

          1. Prior treatment for NSCLC including chemotherapy, biologic response modifier therapy,
             or any investigational drug

          2. Participation in another clinical study within the past four weeks before start of
             therapy or concomitantly with this study

          3. Active brain metastases (stable for &lt;28 days, symptomatic, or requiring concurrent
             steroids or antiepileptic therapy)

          4. Centrally located tumors with radiologic evidence (CT or MRI) of local invasion of
             major blood vessels

          5. Cavitary or necrotic tumors

          6. Sanguinous pleural effusion due to disease or pericardial effusion suspicious for
             disease

          7. Radiotherapy to an area of measurable disease (unless disease progression had been
             documented following completion of therapy)

          8. Radiotherapy within 4 weeks preceding Day 0

          9. Other active malignancy diagnosed within the past 3 years (other than non-melanomatous
             skin cancer)

         10. Gastrointestinal abnormalities that would interfere with intake or absorption of the
             study drug, such as a requirement for intravenous alimentation, prior surgical
             procedures affecting absorption, treatment for peptic ulcer disease within the last 6
             months, active gastrointestinal bleeding unrelated to cancer (as evidenced by either
             hematemesis, hematochezia, or melena in the past 3 months and without endoscopic
             documented resolution), or malabsorption syndromes

         11. Significant cardiovascular disease (i.e., uncontrolled hypertension, myocardial
             infarction within 6 months, unstable angina, serious cardiac arrhythmia, ≥NYHA Grade 2
             congestive heart failure)

         12. History of hemorrhagic or thrombotic event (including transient ischemic attacks) in
             the past 12 months

         13. Clinically significant hemoptysis (1 teaspoon or more) in the past 3 months

         14. Concurrent therapeutic anticoagulation (except heparin flush as needed for maintenance
             of an indwelling intravenous device) or antiplatelet therapy (except chronic low-dose
             daily aspirin &lt;325 mg)

         15. Known hypersensitivity to paclitaxel, carboplatin, or any of their excipients
             including Cremophor® (polyoxyethylated castor oil)

         16. Absolute neutrophil count (ANC) ≤1,500/μl, platelet count ≤100,000/μl, or hemoglobin
             &lt;9 gm/dL

         17. Total bilirubin &gt;1.5 mg/dL (26 μmol/L, SI Unit equivalent), alanine amino transferase
             (ALT) and/or aspartate amino transferase (AST) ≥1.5 X ULN,

         18. Serum creatinine &gt;1.5 mg/dL (&gt;132 μmol/L, SI Unit equivalent)

         19. Persistent hematuria or proteinuria (more than trace)

         20. Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

         21. Pregnancy or breastfeeding

         22. Known or suspected active alcohol or drug abuse

         23. Patients unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

